Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04937319/ ketoconazole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-04937319 / ketoconazole | DRUG | Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6 |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
PF-04937319 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It has been evaluated in clinical trials involving patients with Type 2 Diabetes and in healthy subjects. The drug is being developed by Pfizer, Inc. and is currently in Phase 2 clinical development.
PF-04937319 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of Type 2 Diabetes Mellitus.
PF-04937319 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug has completed Phase 1 and Phase 2 trials, including a Phase 2 study comparing it to glimepiride in patients with Type 2 Diabetes on metformin.
PF-04937319 has been studied in four completed clinical trials. These include NCT01044537 and NCT01272804, which assessed safety, tolerability, and pharmacokinetics in patients with Type 2 Diabetes. NCT01513928 evaluated different formulations in healthy subjects in Singapore, and NCT01517373 was a Phase 2 efficacy and safety study comparing PF-04937319 to glimepiride in patients with Type 2 Diabetes on metformin.
Yes, PF-04937319 has been studied in patients with Type 2 Diabetes Mellitus. Clinical trials have enrolled patients with this condition, including a Phase 2 study with 304 participants that compared the drug to glimepiride in patients also taking metformin. The trials were conducted in multiple countries, including the United States, Bulgaria, Canada, Hungary, India, Slovakia, and Taiwan.